The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

Completed

Conditions studied: Breast Neoplasms, Tamoxifen

In brief

This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast cancer.

Key facts

Study ID

NCT00830973

Run by

Medco Health Solutions, Inc.

People needed

184

Starts

2007-10-01

Expected to finish

2009-01-01

Last updated by the study team

2009-10-14

Who can join

Age: 50 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patient currently has a pharmacy benefit with Medco for an enrolled client
• Patient has a adjudicated tamoxifen pharmacy claims within the last six months
• Patient is still taking tamoxifen to prevent recurrent breast cancer
• Patient is a natural postmenopausal women 50 years of age or older
• Patient signs consent
• Patient is willing to provide sample for genetic testing
• Physician managing tamoxifen therapy is willing to order pharmacogenetic test

You may not qualify if…

• Patient is male
• Patient is under 50 years old
• Patient has previous history of CYP450 2D6 testing
• Patient is no longer taking tamoxifen
• Patient refuses to sign consent
• Patient wishes to no longer participate after testing
• Patient's physician refuses to order pharmacogenetic test

Where it is running

• Robert Epstein — Franklin Lakes, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.